DeepMed Research

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: rozanolixizumab

First Posted Date: 2024-08-06

Last Posted Date: 2025-02-14

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT06540144

Locations: 🇮🇹
Mg0008 40290, Bologna, Italy
🇵🇱
Mg0008 40734, Lodz, Poland
🇵🇱
Mg0008 40155, Warszawa, Poland

and more 2 locations

A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Minzasolmin tablet formulation under fasting condition
Drug: Minzasolmin Granules in capsule under fasting condition
Drug: Minzasolmin tablet formulation under fed condition

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 18

Registration Number: NCT06533475

Locations: 🇩🇪
Up0152 1001, Berlin, Germany

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Zilucoplan

First Posted Date: 2024-07-19

Last Posted Date: 2024-12-06

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 14

Registration Number: NCT06511076

Locations: 🇳🇱
DV0012 1, Groningen, Netherlands

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis
Psoriatic Arthritis

Interventions: Drug: bimekizumab

First Posted Date: 2024-07-18

Last Posted Date: 2025-04-18

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 90

Registration Number: NCT06506916

Locations: 🇺🇸
Ps0039 50140, Birmingham, Alabama, United States
🇺🇸
Ps0039 50491, Pittsburgh, Pennsylvania, United States
🇩🇪
Ps0039 40775, Witten, Germany

and more 13 locations

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-06-24

Last Posted Date: 2025-02-17

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 31

Registration Number: NCT06471361

Locations: 🇺🇸
Dv0013 50628, New Haven, Connecticut, United States
🇺🇸
Dv0013 50634, Tampa, Florida, United States
🇺🇸
Dv0013 50556, Chapel Hill, North Carolina, United States

and more 8 locations

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Phase 3

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Zilucoplan

First Posted Date: 2024-05-30

Last Posted Date: 2025-03-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 8

Registration Number: NCT06435312

Locations: 🇬🇧
Mg0015 40736, London, United Kingdom
🇺🇸
Mg0015 50168, Chicago, Illinois, United States
🇺🇸
Mg0015 50574, Denton, Texas, United States

and more 6 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab
Drug: placebo
Drug: ustekinumab

First Posted Date: 2024-05-22

Last Posted Date: 2025-05-16

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 168

Registration Number: NCT06425549

Locations: 🇺🇸
Ps0021 50162, Fountain Valley, California, United States
🇺🇸
Ps0021 50161, Los Angeles, California, United States
🇺🇸
Ps0021 50196, Northridge, California, United States

and more 42 locations

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: UCB9741
Drug: Placebo

First Posted Date: 2024-03-18

Last Posted Date: 2025-01-31

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 40

Registration Number: NCT06315335

Locations: 🇺🇸
Up0118 10001, Glendale, California, United States

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Recruiting

Conditions: Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions: Drug: Brivaracetam Film-coated tablet
Drug: Brivaracetam oral solution

First Posted Date: 2024-03-18

Last Posted Date: 2025-03-28

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 120

Registration Number: NCT06315322

Locations: 🇺🇦
Ep0224 20328, Uzhgorod, Ukraine
🇺🇸
Ep0224 50140, Birmingham, Alabama, United States
🇺🇸
Ep0224 50639, Orange, California, United States

and more 19 locations

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: brivaracetam (BRV) tablet
Drug: brivaracetam (BRV) dry syrup

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-31

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 64

Registration Number: NCT06312566

Locations: 🇯🇵
EP0231 1, Sumida-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy